Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries
- PMID: 33466239
- PMCID: PMC7795486
- DOI: 10.3390/cancers13010141
Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries
Abstract
This study aimed to examine the global burden, risk factors, and trends of esophageal cancer based on age, sex, and histological subtype. The data were retrieved from cancer registries database from 48 countries in the period 1980-2017. Temporal patterns of incidence and mortality were evaluated by average annual percent change (AAPC) using joinpoint regression. Associations with risk factors were examined by linear regression. The highest incidence of esophageal cancer was observed in Eastern Asia. The highest incidence of adenocarcinoma (AC) was found in the Netherlands, the United Kingdom, and Ireland. A higher AC/squamous cell carcinoma (SCC) incidence ratio was associated with a higher prevalence of obesity and elevated cholesterol. We observed an incidence increase (including AC and SCC) in some countries, with the Czech Republic (female: AAPC 4.66), Spain (female: 3.41), Norway (male: 3.10), Japan (female: 2.18), Thailand (male: 2.17), the Netherlands (male: 2.11; female: 1.88), and Canada (male: 1.51) showing the most significant increase. Countries with increasing mortality included Thailand (male: 5.24), Austria (female: 3.67), Latvia (male: 2.33), and Portugal (male: 1.12). Although the incidence of esophageal cancer showed an overall decreasing trend, an increasing trend was observed in some countries with high AC/SCC incidence ratios. More preventive measures are needed for these countries.
Keywords: esophageal cancer; histological subtypes; incidence; mortality; risk factors.
Conflict of interest statement
The authors declare no conflict of interest.
Figures






Similar articles
-
Global burden and temporal trends in incidence and mortality of oesophageal cancer.J Adv Res. 2023 Aug;50:135-144. doi: 10.1016/j.jare.2022.10.007. Epub 2022 Oct 20. J Adv Res. 2023. PMID: 36272715 Free PMC article.
-
Disease Burden, Risk Factors, and Recent Trends of Liver Cancer: A Global Country-Level Analysis.Liver Cancer. 2021 Jul;10(4):330-345. doi: 10.1159/000515304. Epub 2021 Mar 30. Liver Cancer. 2021. PMID: 34414121 Free PMC article.
-
Global Incidence and mortality of oesophageal cancer and their correlation with socioeconomic indicators temporal patterns and trends in 41 countries.Sci Rep. 2018 Mar 14;8(1):4522. doi: 10.1038/s41598-018-19819-8. Sci Rep. 2018. PMID: 29540708 Free PMC article.
-
International trends in esophageal cancer incidence rates by histological subtype (1990-2012) and prediction of the rates to 2030.Esophagus. 2022 Oct;19(4):560-568. doi: 10.1007/s10388-022-00927-4. Epub 2022 Jun 11. Esophagus. 2022. PMID: 35689719 Review.
-
Cancers with increasing incidence trends in the United States: 1999 through 2008.CA Cancer J Clin. 2012 Mar-Apr;62(2):118-28. doi: 10.3322/caac.20141. Epub 2012 Jan 4. CA Cancer J Clin. 2012. PMID: 22281605 Review.
Cited by
-
Determinants of survival outcomes among esophageal cancer patients at a national referral hospital in Kenya.Chronic Dis Transl Med. 2022 Nov 20;9(1):20-28. doi: 10.1002/cdt3.52. eCollection 2023 Mar. Chronic Dis Transl Med. 2022. PMID: 36926251 Free PMC article.
-
Updated epidemiology of gastrointestinal cancers in East Asia.Nat Rev Gastroenterol Hepatol. 2023 May;20(5):271-287. doi: 10.1038/s41575-022-00726-3. Epub 2023 Jan 11. Nat Rev Gastroenterol Hepatol. 2023. PMID: 36631716 Review.
-
Inhibition of APLN suppresses cell proliferation and migration and promotes cell apoptosis in esophageal cancer cells <em>in vitro</em>, through activating PI3K/mTOR signaling pathway.Eur J Histochem. 2022 Aug 3;66(3):3336. doi: 10.4081/ejh.2022.3336. Eur J Histochem. 2022. PMID: 35920446 Free PMC article.
-
Tumor-Derived Exosomal miR-143-3p Induces Macrophage M2 Polarization to Cause Radiation Resistance in Locally Advanced Esophageal Squamous Cell Carcinoma.Int J Mol Sci. 2024 May 31;25(11):6082. doi: 10.3390/ijms25116082. Int J Mol Sci. 2024. PMID: 38892269 Free PMC article.
-
Immune characteristics and genetic markers of esophageal cancer by single-cell analysis: implications for immunotherapy.J Thorac Dis. 2023 Apr 28;15(4):1805-1822. doi: 10.21037/jtd-23-317. Epub 2023 Apr 27. J Thorac Dis. 2023. PMID: 37197539 Free PMC article.
References
-
- American Cancer Society Survival Rates for Esophageal Cancer. [(accessed on 10 June 2020)];2020 Available online: https://www.cancer.org/cancer/esophagus-cancer/detection-diagnosis-stagi....
-
- Shapiro J., van Lanschot J.J.B., Hulshof M., van Hagen P., van Berge Henegouwen M.I., Wijnhoven B.P.L., van Laarhoven H.W.M., Nieuwenhuijzen G.A.P., Hospers G.A.P., Bonenkamp J.J., et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–1098. doi: 10.1016/S1470-2045(15)00040-6. - DOI - PubMed
-
- Al-Batran S.E., Homann N., Pauligk C., Goetze T.O., Meiler J., Kasper S., Kopp H.G., Mayer F., Haag G.M., Luley K., et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2/3 trial. Lancet. 2019;393:1948–1957. doi: 10.1016/s0140-6736(18)32557-1. - DOI - PubMed
-
- Wong M.C.S., Hamilton W., Whiteman D.C., Jiang J.Y., Qiao Y., Fung F.D.H., Wang H.H.X., Chiu P.W.Y., Ng E.K.W., Wu J.C.Y., et al. Global Incidence and mortality of oesophageal cancer and their correlation with socioeconomic indicators temporal patterns and trends in 41 countries. Sci. Rep. 2018;8:4522. doi: 10.1038/s41598-018-19819-8. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials